Connor, Clark & Lunn Investment Management (CC&L)’s Regenxbio RGNX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$451K	Sell	37,657 -47,591	-56%	-$395K	﹤0.01%	1412
2026 Q1	$714K	Buy	+85,248	New	+$896K	﹤0.01%	1234
2025 Q1	–	Sell	-13,515	Closed	-$104K	–	1573
2024 Q4	$104K	Sell	13,515 -47,773	-78%	-$449K	﹤0.01%	1359
2024 Q3	$643K	Buy	+61,288	New	+$747K	﹤0.01%	1023
2022 Q2	–	Sell	-44,751	Closed	-$1.49M	–	1181
2022 Q1	$1.49M	Sell	44,751 -20,936	-32%	-$582K	0.01%	573
2021 Q4	$2.15M	Sell	65,687 -11,495	-15%	-$391K	0.01%	509
2021 Q3	$3.23M	Buy	+77,182	New	+$2.78M	0.02%	431
2018 Q4	–	Sell	-7,665	Closed	-$579K	–	1037
2018 Q3	$579K	Buy	+7,665	New	+$552K	﹤0.01%	667

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RGNX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Regenxbio (RGNX) stake by 56% in Q2 2026, selling an estimated $395K and leaving 37,657 shares worth $451K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RGNX in Q3 2018 and has held it in 8 quarters since. The position peaked at $3.23M in Q3 2021. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 37,657 shares of Regenxbio worth $451K as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 47,591 Regenxbio shares in Q2 2026, an estimated $395K.
Regenxbio made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1412 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Regenxbio in Q3 2018 and has held it in 8 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Regenxbio position peaked at $3.23M in Q3 2021.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.